For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
IntegriSense™ 750 is a targeted fluorescent imaging agent comprising a potent, selective non-peptide small molecule integrin avb3 antagonist and a near- infrared (NIR) fluorochrome. IntegriSense 750 has a shorter half life in tissue than IntegriSense 680. IntegriSense 750 washes out of tissues in ~ 96 hours to permit more frequent reinjection of the agent in longitudinal studies. This agent has been developed to enable in vivo visualization and quantification of integrin avb3 in tumor cells as well as in neovasculature, to monitor tumor growth, tumor angiogenesis, and treatment efficacy. Absorbance and fluorescence emission spectra of IntegriSense 750 in 1x PBS.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IntegriSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Angiogenesis, Atherosclerosis, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||750 nm|
Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles associated with atherosclerotic disease, in vivo, would enable a robust additional understanding and analysis of disease progression and therapeutic response in research and drug development. We report the utility of the near infrared (NIR) protease-sensing, ProSense® 750 Fluorescent Pre-clinical Imaging Agent, in combination with the FMT® 2500 Quantitative Pre-clinical Imaging System for the non-invasive quantitative measurement of atherosclerotic disease biology and related response to therapy in apolipoprotein (apo) E-deficient mice in vivo. FMT (Fluorescence Molecular Tomography) imaging measured significant increases in aortic region protease activity with a range of values that were comparable to the range seen in the ex vivo aortic arches assessed by fluorescence reflectance imaging (FRI).
Epifluorescence (2D) imaging of superficially implanted mouse tumor xenograft models offers a fast and simple method for assessing tumor progression or response to therapy. This approach for tumor assessment requires the use of near infrared (NIR) imaging agents specific for different aspects of tumor biology, and this Application Note highlights the ease and utility of multiplex NIR fluorescence imaging to characterize the complex biology within tumors growing in a living mouse.
IntegriSense 750 in vivo fluorescent agent protocol
IntegriSense™ 750 is a targeted fluorescence imaging agent comprising a potent, selective non-peptide small molecule integrin avß3 antagonist and a near-infrared (NIR) fluorochrome. This agent has been developed to enable in vivo visualization and quantification of integrin avß3 expressed in tumor cells as well as in neovasculature, to monitor tumor growth, tumor angiogenesis, and treatment efficacy.